[Evaluation of immune- and mediatormechanisms in experimental lung allotransplant rejection in recipients with and without preimmunisation (author's transl)].
The present study is concerned with immune and mediator mechanisms following experimental lung allotransplantation. The investigations focused on the first set and--following allogenic preimmunisation--second set immune response in untreated as well as immunosuppressively treated recipients. After description of operation procedure and monitoring the hyperacute rejection process occurring in the immunized lung graft recipients was analysed. First, kinetic phenomena of antibody rejection and mediator consumption were investigated, thereafter the rejection within the graft was proved by immunological and biochemical methods. The immuno process was controlled by registration of cytotoxic and donor-organ binding antibodies in blood circulation and eluates of rejected lungs. Characterization of mediator mechanisms included alterations in complement-, coagulation-, and fibrinolytic system as well as in collagenolytic activity. Furthermore the effects of activated mediators on blood cells were proved and the findings were correlated with the functional and histomorphological substrates. Comparing hyperacute lung transplant rejection with that of other organ grafts a divergent participation of secondarily activated mediators, especially fibrinolysis, in reaction could be found. Following characterization of second set immune reaction the second part of the study was concerned with the primary immune response against lung allotransplants. Within this part especially the immunizing effect concerning humoral as well as cellular immunity was described and the influences of an immunosuppressive therapy were investigated. Beside of the control of donor-lung-binding antibodies in blood circulation and in eluates, the specifically immunized cells could be proved by a rosette forming cell-test using donor lung antigen coupled erythrocytes. These tests also were judged concerning their clinical-prognostic values. Basing on these results it was possible to comment specifically on important questions in lung allotransplant rejection.
D000818:Animals; D000906:Antibodies / Q000032:analysis; D001379:Azathioprine / Q000627:therapeutic use; D001772:Blood Cell Count; D003094:Collagen / Q000378:metabolism; D003165:Complement System Proteins; D003602:Cytotoxicity, Immunologic; D004285:Dogs; D005342:Fibrinolysis; D006084:Graft Rejection; D007114:Immunization; D007165:Immunosuppression Therapy; D016040:Lung Transplantation; D008775:Methylprednisolone / Q000627:therapeutic use; D003012:Microbial Collagenase / Q000378:metabolism; D016038:Skin Transplantation; D014184:Transplantation, Homologous; D014357:Trypsin / Q000378:metabolism
D000906:Antibodies; D003094:Collagen; D003165:Complement System Proteins; D014357:Trypsin; D003012:Microbial Collagenase; D001379:Azathioprine; D008775:Methylprednisolone
Untersuchungen zu den Immun- und Mediatormechanismen bei der experimentellen Lungenallotransplantatabstossung im immunisierten und nichtimmunisierten Transplantatempfänger.